198 related articles for article (PubMed ID: 35580945)
21. Cytoreductive nephrectomy for metastatic renal cell carcinoma.
Chery LJ; Karam JA; Wood CG
Clin Adv Hematol Oncol; 2016 Sep; 14(9):696-703. PubMed ID: 27673288
[TBL] [Abstract][Full Text] [Related]
22. External validation of the REMARCC model for the selection of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma: A multicenter retrospective study.
Okita K; Hatakeyama S; Naito S; Numakura K; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Nishiyama H; Ito A; Kojima Y; Habuchi T; Obara W; Tsuchiya N; Ohyama C
Urol Oncol; 2021 Dec; 39(12):836.e11-836.e17. PubMed ID: 34544649
[TBL] [Abstract][Full Text] [Related]
23. Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a real-world setting.
Ljungberg B; Sundqvist P; Lindblad P; Kjellman A; Thorstenson A; Hellström M; Kröger Dahlin BI; Thomasson M; Harmenberg U; Lundstam S
Scand J Urol; 2020 Dec; 54(6):487-492. PubMed ID: 32897123
[TBL] [Abstract][Full Text] [Related]
24. Outcomes following cytoreductive nephrectomy without immediate postoperative systemic therapy for patients with synchronous metastatic renal cell carcinoma.
Andrews JR; Lohse CM; Boorjian SA; Leibovich BC; Thompson H; Costello BA; Bhindi B
Urol Oncol; 2022 Apr; 40(4):166.e1-166.e8. PubMed ID: 35168879
[TBL] [Abstract][Full Text] [Related]
25. Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma.
Laukhtina E; Pradere B; D Andrea D; Rosiello G; Luzzago S; Pecoraro A; Palumbo C; Knipper S; Karakiewicz PI; Margulis V; Quhal F; Sari Motlagh R; Mostafaei H; Mori K; Kimura S; Enikeev D; Shariat SF
Urol Oncol; 2020 Dec; 38(12):936.e7-936.e14. PubMed ID: 32962909
[TBL] [Abstract][Full Text] [Related]
26. Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: single institute experience.
De Gobbi A; Biasoni D; Catanzaro M; Nicolai N; Piva L; Stagni S; Torelli T; Procopio G; Verzoni E; Grassi P; Colecchia M; Paolini B; Spreafico C; Marchianò A; Salvioni R
Tumori; 2018 Oct; 104(5):388-393. PubMed ID: 28085177
[TBL] [Abstract][Full Text] [Related]
27. Metastasectomy in patients with renal cell carcinoma: when and how?
Omid S; Abufaraj M; Remzi M
Curr Opin Urol; 2020 Jul; 30(4):602-609. PubMed ID: 32464043
[TBL] [Abstract][Full Text] [Related]
28. The Association Between Cytoreductive Nephrectomy and Overall Survival in Metastatic Renal Cell Carcinoma with Primary Tumor Size ≤4 cm.
Tappero S; Barletta F; Piccinelli ML; Cano Garcia C; Incesu RB; Morra S; Scheipner L; Tian Z; Parodi S; Dell'Oglio P; Palumbo C; Briganti A; De Cobelli O; Chun FKH; Graefen M; Longo N; Ahyai S; Saad F; Shariat SF; Suardi N; Borghesi M; Terrone C; Karakiewicz PI
Eur Urol Focus; 2023 Sep; 9(5):742-750. PubMed ID: 36906483
[TBL] [Abstract][Full Text] [Related]
29. Long-Term Outcome of Zero-Ischemia Partial Nephrectomy for the Treatment of Multifocal Renal Cell Carcinoma in Renal Transplant Allograft: A Case Report.
Simforoosh N; Nadjafi-Semnani M
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):145-147. PubMed ID: 30777541
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers.
Dragomir A; Nazha S; Tanguay S; Breau RH; Bhindi B; Rendon RA; Kapoor A; Hotte SJ; Basappa N; Fairey A; So AI; Kollmannsberger C; Finelli A; Hansen A; Canil C; Heng D; Lattouf JB; Bjarnason G; Power N; Pouliot F; Wood LA
Eur Urol Focus; 2022 Nov; 8(6):1703-1710. PubMed ID: 34736870
[TBL] [Abstract][Full Text] [Related]
31. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features.
Abel EJ; Master VA; Spiess PE; Raman JD; Shapiro DD; Sexton WJ; Zemp L; Patil D; Lauer K; Allen GO; Matin SF; Karam JA
Eur Urol Oncol; 2024 Apr; 7(2):266-274. PubMed ID: 37442673
[TBL] [Abstract][Full Text] [Related]
32. Renal cell carcinoma and brain metastasis: Questioning the dogma of role for cytoreductive nephrectomy.
Daugherty M; Daugherty E; Jacob J; Shapiro O; Mollapour M; Bratslavsky G
Urol Oncol; 2019 Mar; 37(3):182.e9-182.e15. PubMed ID: 30528396
[TBL] [Abstract][Full Text] [Related]
33. The role of cytoreductive nephrectomy and systemic therapy in the management of tumour thrombus in patients with metastatic renal cell carcinoma.
Mittal A; Al-Ezzi E; Li X; Moloney B; Wilson B; Spiliopoulou P; Sridhar S; Fallah-Rad N; Chung P; Hamilton RJ; O'malley M; Hansen AR
Br J Cancer; 2023 May; 128(10):1888-1896. PubMed ID: 36859686
[TBL] [Abstract][Full Text] [Related]
34. Association Between Systemic Therapy and/or Cytoreductive Nephrectomy and Survival in Contemporary Metastatic Non-clear Cell Renal Cell Carcinoma Patients.
Luzzago S; Palumbo C; Rosiello G; Knipper S; Pecoraro A; Mistretta FA; Tian Z; Musi G; Montanari E; Soulières D; Shariat SF; Saad F; Briganti A; de Cobelli O; Karakiewicz PI
Eur Urol Focus; 2021 May; 7(3):598-607. PubMed ID: 32444303
[TBL] [Abstract][Full Text] [Related]
35. Cytoreductive Nephrectomy in Metastatic Patients with Signs or Symptoms: Implications for Renal Cell Carcinoma Guidelines.
Larcher A; Fallara G; Rosiello G; Re C; Baiamonte G; Agnesi S; Cignoli D; Colandrea G; Basile G; Briganti A; Salonia A; Bertini R; Montorsi F; Capitanio U
Eur Urol; 2020 Sep; 78(3):321-326. PubMed ID: 32507335
[TBL] [Abstract][Full Text] [Related]
36. Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approach.
Liu WK; Lam JM; Butters T; Grant M; Jackson-Spence F; Bex A; Powles T; Szabados B
World J Urol; 2020 Dec; 38(12):3199-3205. PubMed ID: 32128610
[TBL] [Abstract][Full Text] [Related]
37. Rapid development and recurrence of translocation renal cell carcinoma.
Kinnear N; Wreghitt S; Hennessey DB; Liodakis P
BMJ Case Rep; 2017 Jun; 2017():. PubMed ID: 28611168
[TBL] [Abstract][Full Text] [Related]
38. Definitions and unmet needs in the management of oligomestatic renal cell carcinoma in the modern era.
Francolini G; Campi R; Ciccarese C;
Curr Opin Urol; 2024 Jul; 34(4):300-306. PubMed ID: 38595192
[TBL] [Abstract][Full Text] [Related]
39. Understanding and integrating cytoreductive nephrectomy with immune checkpoint inhibitors in the management of metastatic RCC.
Das A; Shapiro DD; Craig JK; Abel EJ
Nat Rev Urol; 2023 Nov; 20(11):654-668. PubMed ID: 37400492
[TBL] [Abstract][Full Text] [Related]
40. The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy.
DiNatale RG; Xie W; Becerra MF; Silagy AW; Attalla K; Sanchez A; Mano R; Marcon J; Blum KA; Benfante NE; Voss MH; Motzer RJ; Coleman J; Choueiri TK; Reznik E; Russo P; Heng DYC; Hakimi AA
Eur Urol Oncol; 2020 Feb; 3(1):47-56. PubMed ID: 31735646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
